During the last session, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s traded shares were 3.86 million, with the beta value of the company hitting 1.18. At the end of the trading day, the stock’s price was $9.56, reflecting an intraday loss of -8.43% or -$0.88. The 52-week high for the AUPH share is $13.41, that puts it down -40.27 from that peak though still a striking 57.43% gain since the share price plummeted to a 52-week low of $4.07. The company’s market capitalization is $1.38B, and the average intraday trading volume over the past 10 days was 2.69 million shares, and the average trade volume was 3.13 million shares over the past three months.

Aurinia Pharmaceuticals Inc. (AUPH) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.10. AUPH has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.18.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) trade information

Aurinia Pharmaceuticals Inc. (AUPH) registered a -8.43% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.43% in intraday trading to $9.56 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -10.99%, and it has moved by -14.41% in 30 days. Based on these gigs, the overall price performance for the year is -15.47%. The short interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is 16.71 million shares and it means that shorts have 5.46 day(s) to cover.

The consensus price target of analysts on Wall Street is $13.71, which implies an increase of 30.27% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $15.00 respectively. As a result, AUPH is trading at a discount of -56.9% off the target high and -25.52% off the low.

Aurinia Pharmaceuticals Inc. (AUPH) estimates and forecasts

Statistics show that Aurinia Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Aurinia Pharmaceuticals Inc. (AUPH) shares have gone up 105.59% during the last six months, with a year-to-date growth rate less than the industry average at 6.58% against 13.90. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 28.00% this quarter and then drop -183.30% in the quarter after that. In the rating firms’ projections, revenue will increase 17.10% compared to the previous financial year.

Revenue for the current quarter is expected to be $38.15 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $40.37 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $28.19 million and $55.78 million respectively. In this case, analysts expect current quarter sales to grow by 35.30% and then drop by -27.60% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.70%. While earnings are projected to return 45.50% in 2023.

AUPH Dividends

Aurinia Pharmaceuticals Inc. is due to release its next quarterly earnings between August 02 and August 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s Major holders

Aurinia Pharmaceuticals Inc. insiders own 7.07% of total outstanding shares while institutional holders control 38.24%, with the float percentage being 41.15%. Blackrock Inc. is the largest shareholder of the company, while 254 institutions own stock in it. As of Mar 30, 2023, the company held over 7.9 million shares (or 5.53% of all shares), a total value of $86.62 million in shares.

The next largest institutional holding, with 4.17 million shares, is of Armistice Capital, LLC’s that is approximately 2.92% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $45.73 million.

Also, the Mutual Funds coming in first place with the largest holdings of Aurinia Pharmaceuticals Inc. (AUPH) shares are iShares Russell 2000 ETF and Fidelity Small Cap Index Fund. Data provided on Feb 27, 2023 indicates that iShares Russell 2000 ETF owns about 2.96 million shares. This amounts to just over 2.07 percent of the company’s overall shares, with a $26.92 million market value. The same data shows that the other fund manager holds slightly less at 1.11 million, or about 0.77% of the stock, which is worth about $10.0 million.